The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study
OBJECTIVE To estimate and compare the prevalence and associated bother of lower urinary tract symptoms (LUTS) in the general populations of the USA, UK and Sweden using current International Continence Society (ICS) definitions, as no previous population‐based studies evaluating the prevalence of LU...
Saved in:
| Published in | BJU international Vol. 104; no. 3; pp. 352 - 360 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.08.2009
Wiley-Blackwell |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | OBJECTIVE
To estimate and compare the prevalence and associated bother of lower urinary tract symptoms (LUTS) in the general populations of the USA, UK and Sweden using current International Continence Society (ICS) definitions, as no previous population‐based studies evaluating the prevalence of LUTS in the USA, using the 2002 ICS definitions, have been conducted.
SUBJECTS AND METHODS
This cross‐sectional, population‐representative survey was conducted via the Internet in the USA, the UK and Sweden. Members of Internet‐based panels were randomly selected to receive an e‐mailed invitation to participate. If interested, respondents selected a link to an informed consent page, followed by the survey. Participants were asked to rate how often they experienced individual LUTS during the previous 4 weeks, on a five‐point Likert scale, and, if experienced, how much the symptom bothered them. Descriptive statistics were used to summarize and present the data.
RESULTS
Responses rates for the USA, the UK and Sweden were 59.6%, 60.6% and 52.3%, respectively, with a final sample of 30 000 (USA 20 000; UK 7500; Sweden 2500). The mean age (range) of the participants was 56.6 (40–99) years; the mean percentages for race were 82.9% white, 6.7% black, 6.0% Hispanic and 4.4% Asian/other. The prevalence of LUTS was defined by two symptom frequency thresholds, i.e. at least ‘sometimes’ and at least ‘often’ for all LUTS except incontinence, where frequency thresholds were at least ‘a few times per month’ and at least ‘a few times per week’. The prevalence of at least one LUTS at least ‘sometimes’ was 72.3% for men and 76.3% for women, and 47.9% and 52.5% for at least ‘often’ for men and women, respectively. For most LUTS, at least half of the participants were bothered ‘somewhat’ or more using a frequency threshold of at least ‘sometimes’. For a threshold of at least ‘often’, ‘somewhat’ or more bother was reported by ≥70% of participants except for terminal dribble in men and split stream in women.
CONCLUSION
In this large population study of three countries, LUTS are highly prevalent among men and women aged >40 years. In general, LUTS experienced ‘often’ or more are bothersome to most people. |
|---|---|
| AbstractList | To estimate and compare the prevalence and associated bother of lower urinary tract symptoms (LUTS) in the general populations of the USA, UK and Sweden using current International Continence Society (ICS) definitions, as no previous population-based studies evaluating the prevalence of LUTS in the USA, using the 2002 ICS definitions, have been conducted.OBJECTIVETo estimate and compare the prevalence and associated bother of lower urinary tract symptoms (LUTS) in the general populations of the USA, UK and Sweden using current International Continence Society (ICS) definitions, as no previous population-based studies evaluating the prevalence of LUTS in the USA, using the 2002 ICS definitions, have been conducted.This cross-sectional, population-representative survey was conducted via the Internet in the USA, the UK and Sweden. Members of Internet-based panels were randomly selected to receive an e-mailed invitation to participate. If interested, respondents selected a link to an informed consent page, followed by the survey. Participants were asked to rate how often they experienced individual LUTS during the previous 4 weeks, on a five-point Likert scale, and, if experienced, how much the symptom bothered them. Descriptive statistics were used to summarize and present the data.SUBJECTS AND METHODSThis cross-sectional, population-representative survey was conducted via the Internet in the USA, the UK and Sweden. Members of Internet-based panels were randomly selected to receive an e-mailed invitation to participate. If interested, respondents selected a link to an informed consent page, followed by the survey. Participants were asked to rate how often they experienced individual LUTS during the previous 4 weeks, on a five-point Likert scale, and, if experienced, how much the symptom bothered them. Descriptive statistics were used to summarize and present the data.Responses rates for the USA, the UK and Sweden were 59.6%, 60.6% and 52.3%, respectively, with a final sample of 30,000 (USA 20,000; UK 7500; Sweden 2500). The mean age (range) of the participants was 56.6 (40-99) years; the mean percentages for race were 82.9% white, 6.7% black, 6.0% Hispanic and 4.4% Asian/other. The prevalence of LUTS was defined by two symptom frequency thresholds, i.e. at least 'sometimes' and at least 'often' for all LUTS except incontinence, where frequency thresholds were at least 'a few times per month' and at least 'a few times per week'. The prevalence of at least one LUTS at least 'sometimes' was 72.3% for men and 76.3% for women, and 47.9% and 52.5% for at least 'often' for men and women, respectively. For most LUTS, at least half of the participants were bothered 'somewhat' or more using a frequency threshold of at least 'sometimes'. For a threshold of at least 'often', 'somewhat' or more bother was reported by > or =70% of participants except for terminal dribble in men and split stream in women.RESULTSResponses rates for the USA, the UK and Sweden were 59.6%, 60.6% and 52.3%, respectively, with a final sample of 30,000 (USA 20,000; UK 7500; Sweden 2500). The mean age (range) of the participants was 56.6 (40-99) years; the mean percentages for race were 82.9% white, 6.7% black, 6.0% Hispanic and 4.4% Asian/other. The prevalence of LUTS was defined by two symptom frequency thresholds, i.e. at least 'sometimes' and at least 'often' for all LUTS except incontinence, where frequency thresholds were at least 'a few times per month' and at least 'a few times per week'. The prevalence of at least one LUTS at least 'sometimes' was 72.3% for men and 76.3% for women, and 47.9% and 52.5% for at least 'often' for men and women, respectively. For most LUTS, at least half of the participants were bothered 'somewhat' or more using a frequency threshold of at least 'sometimes'. For a threshold of at least 'often', 'somewhat' or more bother was reported by > or =70% of participants except for terminal dribble in men and split stream in women.In this large population study of three countries, LUTS are highly prevalent among men and women aged >40 years. In general, LUTS experienced 'often' or more are bothersome to most people.CONCLUSIONIn this large population study of three countries, LUTS are highly prevalent among men and women aged >40 years. In general, LUTS experienced 'often' or more are bothersome to most people. To estimate and compare the prevalence and associated bother of lower urinary tract symptoms (LUTS) in the general populations of the USA, UK and Sweden using current International Continence Society (ICS) definitions, as no previous population-based studies evaluating the prevalence of LUTS in the USA, using the 2002 ICS definitions, have been conducted. This cross-sectional, population-representative survey was conducted via the Internet in the USA, the UK and Sweden. Members of Internet-based panels were randomly selected to receive an e-mailed invitation to participate. If interested, respondents selected a link to an informed consent page, followed by the survey. Participants were asked to rate how often they experienced individual LUTS during the previous 4 weeks, on a five-point Likert scale, and, if experienced, how much the symptom bothered them. Descriptive statistics were used to summarize and present the data. Responses rates for the USA, the UK and Sweden were 59.6%, 60.6% and 52.3%, respectively, with a final sample of 30,000 (USA 20,000; UK 7500; Sweden 2500). The mean age (range) of the participants was 56.6 (40-99) years; the mean percentages for race were 82.9% white, 6.7% black, 6.0% Hispanic and 4.4% Asian/other. The prevalence of LUTS was defined by two symptom frequency thresholds, i.e. at least 'sometimes' and at least 'often' for all LUTS except incontinence, where frequency thresholds were at least 'a few times per month' and at least 'a few times per week'. The prevalence of at least one LUTS at least 'sometimes' was 72.3% for men and 76.3% for women, and 47.9% and 52.5% for at least 'often' for men and women, respectively. For most LUTS, at least half of the participants were bothered 'somewhat' or more using a frequency threshold of at least 'sometimes'. For a threshold of at least 'often', 'somewhat' or more bother was reported by > or =70% of participants except for terminal dribble in men and split stream in women. In this large population study of three countries, LUTS are highly prevalent among men and women aged >40 years. In general, LUTS experienced 'often' or more are bothersome to most people. OBJECTIVE To estimate and compare the prevalence and associated bother of lower urinary tract symptoms (LUTS) in the general populations of the USA, UK and Sweden using current International Continence Society (ICS) definitions, as no previous population‐based studies evaluating the prevalence of LUTS in the USA, using the 2002 ICS definitions, have been conducted. SUBJECTS AND METHODS This cross‐sectional, population‐representative survey was conducted via the Internet in the USA, the UK and Sweden. Members of Internet‐based panels were randomly selected to receive an e‐mailed invitation to participate. If interested, respondents selected a link to an informed consent page, followed by the survey. Participants were asked to rate how often they experienced individual LUTS during the previous 4 weeks, on a five‐point Likert scale, and, if experienced, how much the symptom bothered them. Descriptive statistics were used to summarize and present the data. RESULTS Responses rates for the USA, the UK and Sweden were 59.6%, 60.6% and 52.3%, respectively, with a final sample of 30 000 (USA 20 000; UK 7500; Sweden 2500). The mean age (range) of the participants was 56.6 (40–99) years; the mean percentages for race were 82.9% white, 6.7% black, 6.0% Hispanic and 4.4% Asian/other. The prevalence of LUTS was defined by two symptom frequency thresholds, i.e. at least ‘sometimes’ and at least ‘often’ for all LUTS except incontinence, where frequency thresholds were at least ‘a few times per month’ and at least ‘a few times per week’. The prevalence of at least one LUTS at least ‘sometimes’ was 72.3% for men and 76.3% for women, and 47.9% and 52.5% for at least ‘often’ for men and women, respectively. For most LUTS, at least half of the participants were bothered ‘somewhat’ or more using a frequency threshold of at least ‘sometimes’. For a threshold of at least ‘often’, ‘somewhat’ or more bother was reported by ≥70% of participants except for terminal dribble in men and split stream in women. CONCLUSION In this large population study of three countries, LUTS are highly prevalent among men and women aged >40 years. In general, LUTS experienced ‘often’ or more are bothersome to most people. |
| Author | Sexton, Chris C. Kaplan, Steven Thompson, Christine L. Kopp, Zoe S. Aiyer, Lalitha P. Irwin, Debra Coyne, Karin S. Chapple, Christopher R. Tubaro, Andrea Wein, Alan J. Milsom, Ian |
| Author_xml | – sequence: 1 givenname: Karin S. surname: Coyne fullname: Coyne, Karin S. – sequence: 2 givenname: Chris C. surname: Sexton fullname: Sexton, Chris C. – sequence: 3 givenname: Christine L. surname: Thompson fullname: Thompson, Christine L. – sequence: 4 givenname: Ian surname: Milsom fullname: Milsom, Ian – sequence: 5 givenname: Debra surname: Irwin fullname: Irwin, Debra – sequence: 6 givenname: Zoe S. surname: Kopp fullname: Kopp, Zoe S. – sequence: 7 givenname: Christopher R. surname: Chapple fullname: Chapple, Christopher R. – sequence: 8 givenname: Steven surname: Kaplan fullname: Kaplan, Steven – sequence: 9 givenname: Andrea surname: Tubaro fullname: Tubaro, Andrea – sequence: 10 givenname: Lalitha P. surname: Aiyer fullname: Aiyer, Lalitha P. – sequence: 11 givenname: Alan J. surname: Wein fullname: Wein, Alan J. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21727928$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19281467$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkdtu1DAQhi1URA_wCsg3oCKxwU68TrYSSKUqx5W42F2JO8trT8Arxw52wjavwFPjNNsicVVfjEcz3_wjzX-Kjpx3gBCmJKPpvdlllHE2Y5R8z3JCFhmpWF5mN4_QyX3j6C4nC36MTmPcEZIKfP4EHdNFXqW8PEF_1j8BtwF-SwtOAfY1tn4PAffBOBkG3AWpOhyHpu18E_H5crNevcLG4S4NblaXr6fkK5ZO49UeNLgLHCD2tou4Dr657V-3RkNjvPU_hnHHqILPU3WSi12vh6focS1thGeH_wxtPlyvrz7Nlt8-fr66XM4U40U5k6yEShZbTSTnZZ2zqtgCTVFqNU8tNZc8hVrnC6UYo5qwukpcSWstCeXFGXo56bbB_-ohdqIxUYG10oHvo-AlW_B0qAQ-P4D9tgEt2mCadBJxd70EvDgAMipp6yCdMvGey2mZl4lNXDVxKvgYA9T_pIgYDRU7MXolRt_EaKi4NVTcpNF3_40q08nOeJeMMfYhAm8ngb2xMDx4sXj_ZTNmxV82n7kI |
| CitedBy_id | crossref_primary_10_1097_MD_0000000000011554 crossref_primary_10_1097_MOU_0000000000000108 crossref_primary_10_1186_s13063_021_05661_3 crossref_primary_10_1016_j_juro_2013_11_019 crossref_primary_10_1590_s1677_5538_ibju_2019_0234 crossref_primary_10_3390_medicina60030389 crossref_primary_10_1111_bju_14081 crossref_primary_10_1002_nau_22704 crossref_primary_10_1097_JWH_0000000000000209 crossref_primary_10_1016_j_acuroe_2022_03_001 crossref_primary_10_1007_s00345_018_2410_8 crossref_primary_10_1007_s11934_011_0206_0 crossref_primary_10_7748_ns_2022_e11821 crossref_primary_10_1517_14740338_2016_1160055 crossref_primary_10_1016_j_aju_2013_07_005 crossref_primary_10_1111_j_1464_410X_2009_08447_x crossref_primary_10_1586_eog_12_20 crossref_primary_10_1186_1447_056X_10_7 crossref_primary_10_7717_peerj_9039 crossref_primary_10_1186_s12889_020_08992_z crossref_primary_10_1016_j_urology_2020_07_028 crossref_primary_10_1016_j_purol_2023_01_002 crossref_primary_10_1097_MOU_0000000000000127 crossref_primary_10_1016_j_urology_2015_04_002 crossref_primary_10_37586_2686_8636_1_2022_58_63 crossref_primary_10_1097_JWH_0000000000000211 crossref_primary_10_1007_s00345_023_04677_5 crossref_primary_10_1111_bju_12904 crossref_primary_10_1590_s1677_5538_ibju_2023_0546 crossref_primary_10_12968_bjmh_2018_7_2_85 crossref_primary_10_1002_brb3_2268 crossref_primary_10_3810_pgm_2013_07_2673 crossref_primary_10_1007_s00192_017_3319_2 crossref_primary_10_1016_j_mayocp_2011_09_004 crossref_primary_10_7224_1537_2073_2013_040 crossref_primary_10_1111_ijcp_12541 crossref_primary_10_1080_14656566_2025_2453586 crossref_primary_10_1111_ijcp_12302 crossref_primary_10_1038_s41391_021_00419_z crossref_primary_10_1002_nau_23930 crossref_primary_10_1097_MOU_0000000000000379 crossref_primary_10_1111_bju_15191 crossref_primary_10_2217_ahe_12_53 crossref_primary_10_1177_1756287215591763 crossref_primary_10_3390_jcm10112314 crossref_primary_10_1016_j_acuro_2021_09_008 crossref_primary_10_1016_j_cont_2022_100521 crossref_primary_10_1097_JWH_0000000000000224 crossref_primary_10_3390_ijerph16173170 crossref_primary_10_2196_54046 crossref_primary_10_1016_j_ajur_2021_12_010 crossref_primary_10_1111_ijcp_12318 crossref_primary_10_1016_j_conctc_2019_100514 crossref_primary_10_4111_icu_2018_59_3_166 crossref_primary_10_1016_j_eururo_2011_07_049 crossref_primary_10_24911_IJMDC_51_1620473751 crossref_primary_10_1177_2051415817693466 crossref_primary_10_1016_j_eururo_2015_07_043 crossref_primary_10_23950_jcmk_13328 crossref_primary_10_1128_JCM_03314_12 crossref_primary_10_1177_1756287210373757 crossref_primary_10_1111_j_1464_410X_2009_08438_x crossref_primary_10_1159_000504611 crossref_primary_10_1016_j_prnil_2017_02_001 crossref_primary_10_12968_bjcn_2024_0161 crossref_primary_10_1136_bmjopen_2021_056234 crossref_primary_10_2217_ahe_11_65 crossref_primary_10_5213_inj_1836188_094 crossref_primary_10_1007_s00345_009_0490_1 crossref_primary_10_1007_s40266_018_0621_8 crossref_primary_10_1007_s40271_014_0062_3 crossref_primary_10_1002_pros_21421 crossref_primary_10_1016_j_jogoh_2021_102095 crossref_primary_10_1016_j_juro_2017_04_097 crossref_primary_10_1002_nau_24074 crossref_primary_10_1186_s12905_023_02556_0 crossref_primary_10_1007_s00192_018_3768_2 crossref_primary_10_1093_ageing_afz200 crossref_primary_10_1016_j_eururo_2010_06_007 crossref_primary_10_1016_j_neurom_2022_09_006 crossref_primary_10_1111_luts_12210 crossref_primary_10_1111_luts_12452 crossref_primary_10_1016_j_eururo_2012_10_016 crossref_primary_10_28982_josam_739891 crossref_primary_10_1111_iju_12519 crossref_primary_10_1111_luts_12461 crossref_primary_10_1111_j_1442_2042_2011_02730_x crossref_primary_10_1016_j_urology_2021_01_039 crossref_primary_10_1096_fj_14_255885 crossref_primary_10_1185_03007995_2015_1032917 crossref_primary_10_1093_ageing_afv077 crossref_primary_10_3389_fpsyt_2024_1140113 crossref_primary_10_1007_s13670_013_0075_0 crossref_primary_10_1111_bju_14182 crossref_primary_10_1097_01_PGO_0000734820_44805_63 crossref_primary_10_1111_j_1749_771X_2012_01140_x crossref_primary_10_1111_iju_12501 crossref_primary_10_1097_HNP_0000000000000166 crossref_primary_10_1111_ases_12197 crossref_primary_10_1002_ijgo_15705 crossref_primary_10_1186_s12905_024_03103_1 crossref_primary_10_1002_14651858_CD006375_pub4 crossref_primary_10_12968_pnur_2016_27_7_319 crossref_primary_10_5534_wjmh_2015_33_2_81 crossref_primary_10_1007_s00192_020_04343_z crossref_primary_10_1016_j_physbeh_2015_02_021 crossref_primary_10_1089_end_2024_0008 crossref_primary_10_3390_metabo12070649 crossref_primary_10_21860_medflum2017_182959 crossref_primary_10_1016_j_juro_2010_04_012 crossref_primary_10_1038_s41598_023_44862_5 crossref_primary_10_1080_21681805_2021_2002403 crossref_primary_10_1186_s12894_018_0377_9 crossref_primary_10_1590_s1677_5538_ibju_2018_0556 crossref_primary_10_1186_s12894_021_00816_5 crossref_primary_10_1007_s11136_020_02731_y crossref_primary_10_1016_j_urpr_2015_10_004 crossref_primary_10_1589_jpts_30_544 crossref_primary_10_1111_ijcp_12727 crossref_primary_10_1111_luts_12368 crossref_primary_10_1038_s41598_018_20216_4 crossref_primary_10_1080_09593985_2018_1443359 crossref_primary_10_1007_s00345_014_1411_5 crossref_primary_10_1016_j_ogc_2009_08_002 crossref_primary_10_1002_nau_22428 crossref_primary_10_1016_j_cger_2010_02_006 crossref_primary_10_1007_s40618_013_0018_9 crossref_primary_10_1016_j_eursup_2010_04_004 crossref_primary_10_1089_end_2013_0805 crossref_primary_10_1111_j_1365_2648_2010_05341_x crossref_primary_10_1080_13685538_2021_1920911 crossref_primary_10_1111_j_1464_410X_2009_08369_x crossref_primary_10_23922_jarc_2023_040 crossref_primary_10_1371_journal_pone_0223734 crossref_primary_10_2147_IJGM_S338499 crossref_primary_10_1371_journal_pone_0268547 crossref_primary_10_17826_cumj_908652 crossref_primary_10_1111_aogs_13149 crossref_primary_10_1111_bju_13162 crossref_primary_10_1016_j_eururo_2014_12_039 crossref_primary_10_1016_j_sleep_2019_02_006 crossref_primary_10_1136_bmj_k4137 crossref_primary_10_1002_14651858_CD011470 crossref_primary_10_1002_nau_21202 crossref_primary_10_1002_nau_23863 crossref_primary_10_2147_DDDT_S373659 crossref_primary_10_1007_s11136_019_02402_7 crossref_primary_10_1186_s12894_019_0525_x crossref_primary_10_1016_j_urology_2012_04_023 crossref_primary_10_7759_cureus_59148 crossref_primary_10_1007_s41972_020_00113_7 crossref_primary_10_4235_agmr_18_0044 crossref_primary_10_1007_s10354_016_0526_2 crossref_primary_10_1111_luts_12105 crossref_primary_10_1016_j_euf_2018_02_016 crossref_primary_10_1002_nau_23770 crossref_primary_10_1172_jci_insight_188780 crossref_primary_10_1177_1557988319882597 crossref_primary_10_1002_nau_23418 crossref_primary_10_1186_s12894_016_0178_y crossref_primary_10_1007_s11884_013_0181_z crossref_primary_10_1186_s41043_024_00725_x crossref_primary_10_1097_nmg_0000000000000124 crossref_primary_10_4103_UROS_UROS_12_20 crossref_primary_10_4103_jcrsm_jcrsm_124_23 crossref_primary_10_1111_luts_12478 crossref_primary_10_1111_j_1471_0528_2011_02930_x crossref_primary_10_1111_bju_15126 crossref_primary_10_12954_PI_14066 crossref_primary_10_1111_luts_12353 crossref_primary_10_1016_j_juro_2013_09_059 crossref_primary_10_1111_luts_12231 crossref_primary_10_1002_nau_22670 crossref_primary_10_1093_function_zqac042 crossref_primary_10_1080_17425255_2020_1714591 crossref_primary_10_3390_healthcare9050555 crossref_primary_10_1038_s41598_020_76846_0 crossref_primary_10_1007_s11884_023_00703_9 crossref_primary_10_1016_j_juro_2012_10_008 crossref_primary_10_11648_j_sjcm_20241302_11 crossref_primary_10_3111_13696998_2013_802240 crossref_primary_10_26442_20751753_2022_7_201791 crossref_primary_10_1093_ptj_pzx020 crossref_primary_10_1097_GRF_0000000000000620 crossref_primary_10_1016_j_transproceed_2019_02_072 crossref_primary_10_1111_bju_14568 crossref_primary_10_6061_clinics_2019_e713 crossref_primary_10_1186_s41043_024_00612_5 crossref_primary_10_1007_s41973_019_0051_1 crossref_primary_10_1007_s13669_018_0238_2 crossref_primary_10_1038_s41598_021_81790_8 crossref_primary_10_1016_j_eururo_2014_12_012 crossref_primary_10_1177_03915603221077599 crossref_primary_10_1253_circj_CJ_21_0278 crossref_primary_10_3390_diagnostics13061193 crossref_primary_10_1002_uro2_79 crossref_primary_10_1016_j_prnil_2017_12_001 crossref_primary_10_1016_j_urology_2011_07_1399 crossref_primary_10_1007_s11136_014_0725_5 crossref_primary_10_1097_WON_0000000000000234 crossref_primary_10_1152_ajprenal_00318_2017 crossref_primary_10_1080_13685538_2017_1358258 crossref_primary_10_1152_ajprenal_00580_2015 crossref_primary_10_4111_icu_2016_57_6_424 crossref_primary_10_3310_RGTW5711 crossref_primary_10_1111_luts_12185 crossref_primary_10_1016_j_purol_2021_02_001 crossref_primary_10_1097_SPV_0000000000000711 crossref_primary_10_1007_s00345_021_03682_w crossref_primary_10_1016_j_sxmr_2017_07_001 crossref_primary_10_1016_j_ajog_2017_12_219 crossref_primary_10_1002_nau_23828 crossref_primary_10_1002_nau_23709 crossref_primary_10_1002_pros_24541 crossref_primary_10_1016_j_hrtlng_2017_01_002 crossref_primary_10_1155_2014_120525 crossref_primary_10_23736_S1973_9087_24_08484_3 crossref_primary_10_1007_s00281_020_00814_z crossref_primary_10_1016_j_mpsur_2014_04_006 crossref_primary_10_1007_s11884_012_0137_8 crossref_primary_10_1371_journal_pone_0104129 crossref_primary_10_1007_s11884_019_00543_6 crossref_primary_10_1002_nau_24706 crossref_primary_10_5534_wjmh_200176 crossref_primary_10_1002_nau_24944 crossref_primary_10_1016_j_euf_2020_12_001 crossref_primary_10_1093_rheumatology_keac052 crossref_primary_10_3390_jpm11080714 crossref_primary_10_3390_jcm10122650 crossref_primary_10_3892_etm_2015_2445 crossref_primary_10_1371_journal_pone_0257506 crossref_primary_10_1186_s12301_021_00124_2 crossref_primary_10_1016_j_purol_2020_09_002 crossref_primary_10_1016_j_ajog_2023_08_017 crossref_primary_10_1016_j_eururo_2011_01_031 crossref_primary_10_4103_1008_682X_154990 crossref_primary_10_1016_j_jfma_2018_03_006 crossref_primary_10_1016_j_ijnurstu_2016_10_005 crossref_primary_10_1007_s00192_011_1587_9 crossref_primary_10_1089_jwh_2024_0790 crossref_primary_10_1371_journal_pone_0083637 crossref_primary_10_1007_s11255_014_0830_y crossref_primary_10_1038_s41585_021_00545_2 crossref_primary_10_1111_jan_12662 crossref_primary_10_1111_aogs_14743 crossref_primary_10_3390_ijerph18020785 crossref_primary_10_1002_nau_23351 crossref_primary_10_1080_03091902_2025_2465708 crossref_primary_10_1016_j_euf_2021_03_024 crossref_primary_10_12965_jer_1632802_401 crossref_primary_10_1002_nau_24688 crossref_primary_10_1007_s10151_017_1653_5 crossref_primary_10_1016_j_juro_2014_11_094 crossref_primary_10_1016_j_fpurol_2023_03_001 crossref_primary_10_1016_j_eururo_2018_09_029 crossref_primary_10_1002_jcph_1107 crossref_primary_10_1007_s40266_020_00783_w crossref_primary_10_1002_nau_24791 crossref_primary_10_1080_21681805_2022_2120066 crossref_primary_10_1007_s11884_010_0057_4 crossref_primary_10_1016_j_jmig_2023_11_013 crossref_primary_10_1242_bio_053447 crossref_primary_10_1097_SPV_0000000000000594 crossref_primary_10_4081_wpph_2024_9790 crossref_primary_10_3111_13696998_2012_666511 crossref_primary_10_1093_jsxmed_qdad138 crossref_primary_10_1097_SPV_0000000000001333 crossref_primary_10_3760_cma_j_issn_0366_6999_20131349 crossref_primary_10_1007_s00192_021_04793_z crossref_primary_10_1002_nau_24344 crossref_primary_10_1002_nau_25430 crossref_primary_10_1021_np500810c crossref_primary_10_1186_1477_7525_12_18 crossref_primary_10_2196_30767 crossref_primary_10_1111_ene_16486 crossref_primary_10_1007_s00192_011_1651_5 crossref_primary_10_1016_j_urology_2020_05_065 crossref_primary_10_1007_s00345_024_05293_7 crossref_primary_10_1111_luts_12193 crossref_primary_10_1177_03915603221078267 crossref_primary_10_1007_s00345_024_05271_z crossref_primary_10_1177_1756287220922425 crossref_primary_10_5213_inj_2014_18_2_86 crossref_primary_10_1016_j_gene_2022_146775 crossref_primary_10_2147_IJGM_S333423 crossref_primary_10_2196_27029 crossref_primary_10_1016_j_jval_2014_09_002 crossref_primary_10_1007_s00192_015_2626_8 crossref_primary_10_1016_j_semerg_2015_12_002 crossref_primary_10_1016_j_pharep_2019_03_004 crossref_primary_10_1007_s00192_013_2183_y crossref_primary_10_1111_j_1464_410X_2012_11593_x crossref_primary_10_1113_JP285583 crossref_primary_10_1007_s40266_014_0237_6 crossref_primary_10_1080_14656566_2024_2362272 crossref_primary_10_5812_numonthly_34342 crossref_primary_10_1093_fampra_cmab044 crossref_primary_10_1007_s00192_016_3080_y crossref_primary_10_1177_2377960818811773 crossref_primary_10_1016_j_contre_2023_100029 crossref_primary_10_1586_14737167_2015_1011132 crossref_primary_10_2214_AJR_13_10681 crossref_primary_10_1016_j_clinph_2024_07_019 crossref_primary_10_1055_s_0038_1667184 crossref_primary_10_1016_j_ejogrb_2020_04_039 crossref_primary_10_1111_j_1464_410X_2010_10013_x crossref_primary_10_1007_s11255_013_0621_x crossref_primary_10_1136_bmjopen_2016_013737 crossref_primary_10_1007_s00192_018_3796_y crossref_primary_10_1016_j_prnil_2016_02_001 crossref_primary_10_1002_nau_23434 crossref_primary_10_1007_s00192_018_3644_0 crossref_primary_10_1002_nau_23315 crossref_primary_10_1177_15579883231176667 crossref_primary_10_5213_inj_2015_19_2_120 crossref_primary_10_1111_ijcp_13299 crossref_primary_10_1159_000530627 crossref_primary_10_1097_us9_0000000000000014 crossref_primary_10_1016_j_urology_2013_05_035 crossref_primary_10_1016_j_urology_2016_11_008 crossref_primary_10_1016_j_euf_2021_09_016 crossref_primary_10_1016_j_acuroe_2020_12_003 crossref_primary_10_1007_s00192_012_1829_5 crossref_primary_10_1002_nau_24871 crossref_primary_10_1002_nau_22211 crossref_primary_10_1089_end_2021_0788 crossref_primary_10_1002_nau_24870 crossref_primary_10_1007_s12325_017_0577_9 crossref_primary_10_1111_j_1464_410X_2010_09845_x crossref_primary_10_1002_nau_23787 crossref_primary_10_1002_nau_22213 crossref_primary_10_1177_1756287215614237 crossref_primary_10_1016_j_autneu_2009_10_006 crossref_primary_10_1016_j_euf_2021_12_016 crossref_primary_10_3390_jcm14010284 crossref_primary_10_3389_fphys_2021_747144 crossref_primary_10_1007_s11884_022_00673_4 crossref_primary_10_1111_bju_14849 crossref_primary_10_1145_3470132 crossref_primary_10_1111_iju_12074 crossref_primary_10_3390_brainsci11060712 crossref_primary_10_3928_00989134_20210510_03 crossref_primary_10_1002_nau_24421 crossref_primary_10_1111_iju_14492 crossref_primary_10_1016_j_ijgo_2012_01_021 crossref_primary_10_2196_ijmr_2101 crossref_primary_10_1016_j_juro_2017_07_010 crossref_primary_10_3389_fphar_2021_626155 crossref_primary_10_1016_j_acuroe_2016_03_009 crossref_primary_10_1111_ggi_14279 crossref_primary_10_5213_inj_2014_18_3_126 crossref_primary_10_1007_s00192_012_1774_3 crossref_primary_10_1007_s00192_020_04392_4 crossref_primary_10_1007_s00345_017_2052_2 crossref_primary_10_5014_ajot_2019_038356 crossref_primary_10_1007_s00192_017_3435_z crossref_primary_10_2217_WHE_15_31 crossref_primary_10_1016_j_purol_2018_08_005 crossref_primary_10_4082_kjfm_19_0012 crossref_primary_10_4155_cli_12_68 crossref_primary_10_1007_s00192_018_3839_4 crossref_primary_10_1093_ageing_aft214 crossref_primary_10_1007_s11884_014_0275_2 crossref_primary_10_1186_s12894_021_00941_1 crossref_primary_10_1097_SPV_0000000000001423 crossref_primary_10_1007_s00192_020_04414_1 crossref_primary_10_1002_nau_22595 crossref_primary_10_1002_nau_22473 crossref_primary_10_1097_SPV_0000000000001427 crossref_primary_10_1097_SPV_0000000000001307 crossref_primary_10_1089_jwh_2024_0743 crossref_primary_10_1016_j_urology_2021_05_032 crossref_primary_10_1002_nau_23446 crossref_primary_10_3390_jcm9124102 crossref_primary_10_1002_nau_23203 crossref_primary_10_1002_nau_24413 crossref_primary_10_1002_nau_25623 crossref_primary_10_1007_s40266_013_0145_1 crossref_primary_10_1111_ijcp_12194 crossref_primary_10_1186_s41687_022_00519_x crossref_primary_10_3834_uij_1944_5784_2012_06_01 crossref_primary_10_1016_j_cont_2023_100578 crossref_primary_10_3390_healthcare11101513 crossref_primary_10_1016_j_urology_2019_10_018 crossref_primary_10_1016_j_ajog_2016_09_104 crossref_primary_10_1111_j_1464_410X_2009_08493_x crossref_primary_10_1371_journal_pone_0109278 crossref_primary_10_1007_s11884_013_0178_7 crossref_primary_10_1002_nau_25374 crossref_primary_10_1007_s00192_015_2696_7 crossref_primary_10_1007_s11884_019_00570_3 crossref_primary_10_1016_j_urology_2013_10_003 crossref_primary_10_1111_ijun_12322 crossref_primary_10_1080_13548506_2019_1595679 crossref_primary_10_1016_j_urpr_2017_02_008 crossref_primary_10_1111_ijcp_12164 crossref_primary_10_1016_j_urology_2010_08_039 crossref_primary_10_1016_j_eururo_2010_03_014 crossref_primary_10_3390_jcm12082859 crossref_primary_10_1016_j_maturitas_2012_04_014 crossref_primary_10_1186_1471_2318_13_47 crossref_primary_10_1038_s41598_024_69301_x crossref_primary_10_1093_ageing_afw252 crossref_primary_10_2174_1389450121666200716202103 crossref_primary_10_1002_nau_24275 crossref_primary_10_1016_j_jogoh_2020_101922 crossref_primary_10_3310_hta24420 crossref_primary_10_1159_000488769 crossref_primary_10_1016_j_urols_2016_10_002 crossref_primary_10_1038_s41585_021_00428_6 crossref_primary_10_1371_journal_pone_0169690 crossref_primary_10_1007_s00404_019_05127_7 crossref_primary_10_1080_13685538_2018_1545834 crossref_primary_10_1111_ijcp_12170 crossref_primary_10_19163_1994_9480_2024_21_2_29_35 crossref_primary_10_3310_hta20070 crossref_primary_10_3109_00365599_2012_702786 crossref_primary_10_1111_iju_13401 crossref_primary_10_1097_CU9_0000000000000196 crossref_primary_10_1007_s11255_013_0586_9 crossref_primary_10_1186_s41512_021_00100_y crossref_primary_10_1007_s11255_024_04153_y crossref_primary_10_1177_1756287215589238 crossref_primary_10_1007_s11884_021_00633_4 crossref_primary_10_1016_j_euf_2022_06_011 crossref_primary_10_1016_j_fmc_2023_01_001 crossref_primary_10_1016_j_mcna_2010_08_025 crossref_primary_10_1016_j_eururo_2013_01_018 crossref_primary_10_1111_j_1464_410X_2009_08371_x crossref_primary_10_1080_13543784_2024_2326023 crossref_primary_10_1002_nau_24067 crossref_primary_10_1007_s11608_010_0349_3 crossref_primary_10_1016_j_urology_2011_09_010 crossref_primary_10_1080_13697137_2018_1543263 crossref_primary_10_1177_09544119211047058 crossref_primary_10_1111_j_1464_410X_2010_09993_x crossref_primary_10_1097_MD_0000000000041108 crossref_primary_10_1016_j_acuro_2020_03_012 crossref_primary_10_1111_ijcp_12141 crossref_primary_10_1016_j_jpsychores_2018_11_015 crossref_primary_10_4111_kju_2014_55_5_300 crossref_primary_10_1080_21681805_2018_1536677 crossref_primary_10_14814_phy2_14792 crossref_primary_10_5213_inj_1630502_251 crossref_primary_10_1111_bju_12650 crossref_primary_10_1177_17562872211053679 crossref_primary_10_1177_1740774512460144 crossref_primary_10_1002_nau_25023 crossref_primary_10_1007_s00345_023_04351_w crossref_primary_10_1097_MOU_0b013e328363fbf1 crossref_primary_10_1111_j_1464_410X_2011_10443_x crossref_primary_10_15406_ppij_2021_09_00353 crossref_primary_10_1016_j_juro_2018_03_134 crossref_primary_10_1002_nur_20457 crossref_primary_10_2147_IJWH_S383651 crossref_primary_10_1038_srep41714 crossref_primary_10_1111_j_1464_410X_2009_08372_x crossref_primary_10_1186_s12889_023_17065_w crossref_primary_10_1007_s11884_013_0199_2 crossref_primary_10_1177_03915603231225632 crossref_primary_10_1111_bph_12567 crossref_primary_10_1186_s12905_023_02592_w crossref_primary_10_1038_s41598_020_77223_7 crossref_primary_10_1186_s12894_018_0376_x crossref_primary_10_2147_RRU_S266400 crossref_primary_10_3390_ijerph17124340 crossref_primary_10_1007_s00404_017_4514_6 crossref_primary_10_1055_a_1492_5287 crossref_primary_10_1002_nau_24004 crossref_primary_10_1002_nau_25456 crossref_primary_10_1007_s11884_019_00527_6 crossref_primary_10_1038_s41391_022_00610_w crossref_primary_10_1089_jwh_2018_7364 crossref_primary_10_1002_nau_24361 crossref_primary_10_1093_cercor_bhu140 crossref_primary_10_1007_s00345_015_1703_4 crossref_primary_10_3390_ijerph19095156 crossref_primary_10_1007_s00345_021_03730_5 crossref_primary_10_1186_s12905_022_01609_0 crossref_primary_10_1016_j_ddstr_2012_02_001 crossref_primary_10_1007_s11884_012_0164_5 crossref_primary_10_1080_02813432_2018_1487377 crossref_primary_10_1097_SPV_0000000000001471 crossref_primary_10_1172_jci_insight_122112 crossref_primary_10_1080_21681805_2018_1505944 crossref_primary_10_1002_tre_867 crossref_primary_10_1016_j_jpag_2019_10_007 crossref_primary_10_1016_j_euf_2022_10_005 crossref_primary_10_1097_GME_0000000000002377 crossref_primary_10_1016_j_ajog_2020_07_029 crossref_primary_10_1016_j_urology_2019_03_014 crossref_primary_10_1002_nau_22295 crossref_primary_10_1097_NNR_0b013e318251d8f6 crossref_primary_10_1111_ijcp_12015 crossref_primary_10_1517_14656566_2011_554396 crossref_primary_10_1016_j_acuro_2015_12_008 crossref_primary_10_5213_inj_2015_19_1_39 crossref_primary_10_1002_14651858_CD013291 crossref_primary_10_1111_ijcp_13582 crossref_primary_10_4103_jmh_JMH_113_20 crossref_primary_10_1111_iju_14411 crossref_primary_10_2147_RRU_S244758 crossref_primary_10_3390_jcm12082803 crossref_primary_10_5213_inj_2040426_213 crossref_primary_10_1186_s12894_017_0294_3 crossref_primary_10_1002_nau_25356 crossref_primary_10_1002_nau_23295 crossref_primary_10_1038_nrurol_2015_301 crossref_primary_10_1002_nau_24020 crossref_primary_10_1016_j_eururo_2014_01_019 crossref_primary_10_18311_jeoh_2025_44087 crossref_primary_10_1002_nau_25238 crossref_primary_10_1002_nau_25118 crossref_primary_10_5534_wjmh_180042 crossref_primary_10_1177_1049732320979168 crossref_primary_10_3390_diagnostics13050986 crossref_primary_10_3390_jcm11174971 crossref_primary_10_1136_bmjinnov_2019_000382 crossref_primary_10_1016_j_cont_2025_101746 crossref_primary_10_1016_j_cont_2024_101320 crossref_primary_10_2147_RRU_S270915 crossref_primary_10_1007_s11884_024_00770_6 crossref_primary_10_1080_13697137_2022_2158730 crossref_primary_10_1186_s12877_020_1474_7 crossref_primary_10_1002_nau_25587 crossref_primary_10_1016_j_vetmic_2015_06_012 crossref_primary_10_2217_nmt_2020_0010 crossref_primary_10_5213_inj_1938010_005 crossref_primary_10_1002_ijgo_15430 crossref_primary_10_1177_1557988317690283 crossref_primary_10_4103_UROS_UROS_110_22 crossref_primary_10_4236_ojog_2015_53021 crossref_primary_10_4111_icu_2019_60_3_142 |
| Cites_doi | 10.1159/000049872 10.1016/S0022-5347(05)65985-X 10.1016/j.eururo.2005.01.011 10.1111/j.1464-410X.2005.05457.x 10.1046/j.1442-2042.2003.00638.x 10.1002/nau.10052 10.1016/S0090-4295(99)00099-0 10.1016/S0022-3999(01)00296-3 10.5694/j.1326-5377.1997.tb138783.x 10.1111/j.1464-410X.2003.04526.x 10.1111/j.1524-4733.2005.04054.x 10.1016/j.eururo.2006.01.007 10.1080/00926230591006502 10.1016/j.eururo.2008.03.109 10.1111/j.1464-410X.1994.tb09182.x 10.1111/j.1464-410X.2004.05001.x 10.1111/j.1464-410X.2005.05720.x 10.1002/nau.20251 10.1016/S0022-5347(17)36966-5 10.1111/j.1464-410X.2008.07598.x 10.1016/j.eururo.2006.09.019 10.1111/j.1743-6109.2006.00239.x 10.1111/j.1464-410X.2008.07653.x 10.1016/j.eururo.2006.06.011 10.1159/000052527 10.1016/S0090-4295(03)00154-7 10.1016/S0022-5347(01)66780-6 10.1097/00008469-200210000-00010 10.1111/j.1464-410X.2004.04930.x 10.1093/fampra/cmh607 10.1016/j.urology.2004.04.056 10.1016/S0022-5347(01)66063-4 10.1089/152460902753668475 10.1111/j.1464-410X.2005.05573.x 10.1016/j.eururo.2005.06.013 10.1097/00005650-200101000-00009 |
| ContentType | Journal Article |
| Copyright | 2009 THE AUTHORS. JOURNAL COMPILATION © 2009 BJU INTERNATIONAL 2009 INIST-CNRS |
| Copyright_xml | – notice: 2009 THE AUTHORS. JOURNAL COMPILATION © 2009 BJU INTERNATIONAL – notice: 2009 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1111/j.1464-410X.2009.08427.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | 360 |
| ExternalDocumentID | 19281467 21727928 10_1111_j_1464_410X_2009_08427_x BJU8427 |
| Genre | article Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GeographicLocations | United Kingdom Sweden United States North America Europe America |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c4637-a47e8a3bd0a667f2483be1483adc57e8c5a68c5fd29cc441d04f87f271fda0163 |
| IEDL.DBID | DR2 |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Fri Jul 11 00:47:46 EDT 2025 Mon Jul 21 05:56:43 EDT 2025 Mon Jul 21 09:14:35 EDT 2025 Tue Jul 01 03:49:40 EDT 2025 Thu Apr 24 22:54:13 EDT 2025 Wed Jan 22 16:45:32 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Nephrology Urinary system disease Prevalence bother Urinary tract disease LUTS prevalence, community-survey Epidemiology Urology Voiding dysfunction Survey Lower urinary tract symptoms Community |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4637-a47e8a3bd0a667f2483be1483adc57e8c5a68c5fd29cc441d04f87f271fda0163 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 19281467 |
| PQID | 67496466 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_67496466 pubmed_primary_19281467 pascalfrancis_primary_21727928 crossref_primary_10_1111_j_1464_410X_2009_08427_x crossref_citationtrail_10_1111_j_1464_410X_2009_08427_x wiley_primary_10_1111_j_1464_410X_2009_08427_x_BJU8427 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | August 2009 |
| PublicationDateYYYYMMDD | 2009-08-01 |
| PublicationDate_xml | – month: 08 year: 2009 text: August 2009 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2009 |
| Publisher | Blackwell Publishing Ltd Wiley-Blackwell |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell |
| References | 2001; 166 2004; 21 2004; 64 2006; 50 2002; 52 2002; 11 1992; 148 2009 1995 1994 2006; 3 2008; 54 2007; 51 2005; 48 2008; 101 1995; 154 2001; 40 2003; 10 2005; 47 2004; 94 2003; 92 2006; 49 2005; 8 2002; 21 2006; 25 1997; 167 2005; 95 2005; 96 2005; 31 1999; 54 1996; 155 2001; 39 2003; 61 1994; 74 e_1_2_8_28_2 e_1_2_8_29_2 e_1_2_8_23_2 e_1_2_8_24_2 Coyne KS (e_1_2_8_25_2) 2009 e_1_2_8_26_2 e_1_2_8_9_2 e_1_2_8_2_2 e_1_2_8_4_2 e_1_2_8_3_2 e_1_2_8_6_2 e_1_2_8_5_2 e_1_2_8_8_2 e_1_2_8_7_2 e_1_2_8_20_2 e_1_2_8_41_2 e_1_2_8_21_2 e_1_2_8_22_2 e_1_2_8_40_2 e_1_2_8_16_2 e_1_2_8_39_2 e_1_2_8_17_2 Snaith R (e_1_2_8_30_2) 1994 e_1_2_8_38_2 e_1_2_8_18_2 e_1_2_8_19_2 e_1_2_8_12_2 e_1_2_8_35_2 e_1_2_8_13_2 e_1_2_8_34_2 e_1_2_8_14_2 e_1_2_8_37_2 e_1_2_8_15_2 e_1_2_8_36_2 Ware J (e_1_2_8_27_2) 1995 e_1_2_8_31_2 e_1_2_8_10_2 e_1_2_8_33_2 e_1_2_8_11_2 e_1_2_8_32_2 |
| References_xml | – volume: 96 start-page: 823 year: 2005 end-page: 7 article-title: Lower urinary tract symptoms in men: self‐perceptions and the concept of bother publication-title: BJU Int – volume: 61 start-page: 1086 year: 2003 end-page: 91 article-title: Comparison of lower urinary tract symptom severity and associated bother between community‐dwelling black and white men: the Olmsted county study of urinary symptoms and health status and the Flint men’s health study publication-title: Urology – volume: 95 start-page: 1013 year: 2005 end-page: 22 article-title: Web‐based research of lower urinary tract symptoms that affect quality of life in elderly Japanese men: analysis using a structural equation model publication-title: BJU Int – volume: 154 start-page: 1770 year: 1995 end-page: 4 article-title: Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? publication-title: J Urol – volume: 166 start-page: 563 year: 2001 end-page: 8 article-title: Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well‐being publication-title: J Urol – volume: 155 start-page: 1965 year: 1996 end-page: 70 article-title: Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older publication-title: J Urol – volume: 49 start-page: 1079 year: 2006 end-page: 86 article-title: The validation of the Patient Perception of Bladder Condition (PPBC): a single‐item global measure for patients with overactive bladder publication-title: Eur Urol – volume: 31 start-page: 385 year: 2005 end-page: 97 article-title: Development of a questionnaire on sexual quality of life in women publication-title: J Sex Marital Ther – volume: 51 start-page: 473 year: 2007 end-page: 7 article-title: Impact of LUTS using bother index in DAN‐PSS‐1 questionnaire publication-title: Eur Urol – volume: 101 start-page: 1274 year: 2008 end-page: 8 article-title: Beyond the cluster: methodological and clinical implications in the Boston Area Community Health survey and EPIC studies publication-title: BJU Int – volume: 39 start-page: 682 year: 2001 end-page: 7 article-title: Male lower urinary tract symptoms and related health care seeking in Germany publication-title: Eur Urol – volume: 101 start-page: 1267 year: 2008 end-page: 73 article-title: Examining lower urinary tract symptom constellations using cluster analysis publication-title: BJU Int – volume: 39 start-page: 72 year: 2001 end-page: 85 article-title: The Work Limitations Questionnaire publication-title: Med Care – volume: 21 start-page: 617 year: 2004 end-page: 22 article-title: Prevalence of distress and symptom severity from the lower urinary tract in men: a population‐based study with the DAN‐PSS questionnaire publication-title: Fam Pract – volume: 96 start-page: 88 year: 2005 end-page: 92 article-title: The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study publication-title: BJU Int – volume: 148 start-page: 1549 year: 1992 end-page: 57 article-title: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association publication-title: J Urol – volume: 40 start-page: 13 year: 2001 end-page: 8 article-title: Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH publication-title: Eur Urol – volume: 167 start-page: 72 year: 1997 end-page: 5 article-title: Troublesome lower urinary tract symptoms in the community: a prevalence study publication-title: Med J Aust – volume: 21 start-page: 167 year: 2002 end-page: 78 article-title: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub‐committee of the International Continence Society publication-title: Neurourol Urodyn – year: 1994 – volume: 50 start-page: 1306 year: 2006 end-page: 15 article-title: Population‐based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study publication-title: Eur Urol – volume: 11 start-page: 277 year: 2002 end-page: 89 article-title: Development of a sexual function questionnaire for clinical trials of female sexual dysfunction publication-title: J Womens Health Gend Based Med – volume: 10 start-page: 364 year: 2003 end-page: 70 article-title: Prevalence or lower urinary tract symptoms in a community‐based survey of men in Turkey publication-title: Int J Urol – volume: 3 start-page: 465 year: 2006 end-page: 75 article-title: Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation publication-title: J Sex Med – volume: 74 start-page: 551 year: 1994 end-page: 5 article-title: Urinary symptoms in the community: how bothersome are they? publication-title: Br J Urol – volume: 8 start-page: 94 year: 2005 end-page: 104 article-title: Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient‐Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation publication-title: Value Health – volume: 64 start-page: 777 year: 2004 end-page: 82 article-title: Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation publication-title: Urology – volume: 47 start-page: 817 year: 2005 end-page: 23 article-title: Lower urinary tract symptoms in the Danish population: a population‐based study of symptom prevalence, health‐care seeking behavior and prevalence of treatment in elderly males and females publication-title: Eur Urol – volume: 48 start-page: 601 year: 2005 end-page: 7 article-title: Relationship between lower urinary tract symptoms frequency assessed by the IPSS and bothersomeness (SPI) among men older than 50 years old publication-title: Eur Urol – volume: 54 start-page: 563 year: 2008 end-page: 9 article-title: Lower urinary tract symptoms revisited: a broader clinical perspective publication-title: Eur Urol – volume: 54 start-page: 346 year: 1999 end-page: 51 article-title: Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function publication-title: Urology – year: 1995 – year: 2009 article-title: Rationale for the study methods and design of EpiLUTS publication-title: BJU Int – volume: 94 start-page: 327 year: 2004 end-page: 31 article-title: Prevalence of lower urinary tract symptoms in men aged 45–79 years: a population‐based study of 40,000 Swedish men publication-title: BJU Int – volume: 11 start-page: 473 year: 2002 end-page: 9 article-title: Knowledge and opinion on prostate and prevalence of self‐reported BPH and prostate‐related events. A cross‐sectional survey in Italy publication-title: Eur J Cancer Prev – volume: 52 start-page: 69 year: 2002 end-page: 77 article-title: The validity of the Hospital Anxiety and Depression Scale. An updated literature review publication-title: J Psychosom Res – volume: 92 start-page: 943 year: 2003 end-page: 7 article-title: The prevalence of male urinary incontinence in four centres: the UREPIK study publication-title: BJU Int – volume: 94 start-page: 563 year: 2004 end-page: 7 article-title: Men’s experiences of having lower urinary tract symptoms: factors relating to bother publication-title: BJU Int – volume: 25 start-page: 293 year: 2006 article-title: Reviewing the ICS 2002 Terminology Report: the ongoing debate publication-title: Neurourol Urodyn – ident: e_1_2_8_15_2 doi: 10.1159/000049872 – ident: e_1_2_8_17_2 doi: 10.1016/S0022-5347(05)65985-X – ident: e_1_2_8_13_2 doi: 10.1016/j.eururo.2005.01.011 – ident: e_1_2_8_22_2 doi: 10.1111/j.1464-410X.2005.05457.x – ident: e_1_2_8_3_2 doi: 10.1046/j.1442-2042.2003.00638.x – ident: e_1_2_8_2_2 doi: 10.1002/nau.10052 – ident: e_1_2_8_35_2 doi: 10.1016/S0090-4295(99)00099-0 – ident: e_1_2_8_29_2 doi: 10.1016/S0022-3999(01)00296-3 – volume-title: The Hospital Anxiety and Depression Scale Manual year: 1994 ident: e_1_2_8_30_2 – ident: e_1_2_8_8_2 doi: 10.5694/j.1326-5377.1997.tb138783.x – ident: e_1_2_8_16_2 doi: 10.1111/j.1464-410X.2003.04526.x – ident: e_1_2_8_26_2 doi: 10.1111/j.1524-4733.2005.04054.x – ident: e_1_2_8_37_2 – ident: e_1_2_8_28_2 doi: 10.1016/j.eururo.2006.01.007 – ident: e_1_2_8_31_2 doi: 10.1080/00926230591006502 – ident: e_1_2_8_41_2 doi: 10.1016/j.eururo.2008.03.109 – ident: e_1_2_8_21_2 doi: 10.1111/j.1464-410X.1994.tb09182.x – ident: e_1_2_8_19_2 doi: 10.1111/j.1464-410X.2004.05001.x – ident: e_1_2_8_18_2 doi: 10.1111/j.1464-410X.2005.05720.x – ident: e_1_2_8_24_2 doi: 10.1002/nau.20251 – ident: e_1_2_8_36_2 doi: 10.1016/S0022-5347(17)36966-5 – ident: e_1_2_8_39_2 doi: 10.1111/j.1464-410X.2008.07598.x – ident: e_1_2_8_12_2 doi: 10.1016/j.eururo.2006.09.019 – ident: e_1_2_8_34_2 doi: 10.1111/j.1743-6109.2006.00239.x – ident: e_1_2_8_40_2 doi: 10.1111/j.1464-410X.2008.07653.x – ident: e_1_2_8_20_2 doi: 10.1016/j.eururo.2006.06.011 – ident: e_1_2_8_6_2 doi: 10.1159/000052527 – ident: e_1_2_8_9_2 doi: 10.1016/S0090-4295(03)00154-7 – ident: e_1_2_8_11_2 doi: 10.1016/S0022-5347(01)66780-6 – ident: e_1_2_8_5_2 doi: 10.1097/00008469-200210000-00010 – ident: e_1_2_8_4_2 doi: 10.1111/j.1464-410X.2004.04930.x – ident: e_1_2_8_23_2 doi: 10.1093/fampra/cmh607 – ident: e_1_2_8_33_2 doi: 10.1016/j.urology.2004.04.056 – ident: e_1_2_8_7_2 doi: 10.1016/S0022-5347(01)66063-4 – volume-title: SF12. How to Score the SF12 Physical and Mental Health Summary Scales year: 1995 ident: e_1_2_8_27_2 – ident: e_1_2_8_32_2 doi: 10.1089/152460902753668475 – ident: e_1_2_8_14_2 doi: 10.1111/j.1464-410X.2005.05573.x – ident: e_1_2_8_10_2 doi: 10.1016/j.eururo.2005.06.013 – ident: e_1_2_8_38_2 doi: 10.1097/00005650-200101000-00009 – year: 2009 ident: e_1_2_8_25_2 article-title: Rationale for the study methods and design of EpiLUTS publication-title: BJU Int |
| SSID | ssj0014665 |
| Score | 2.4951694 |
| Snippet | OBJECTIVE
To estimate and compare the prevalence and associated bother of lower urinary tract symptoms (LUTS) in the general populations of the USA, UK and... To estimate and compare the prevalence and associated bother of lower urinary tract symptoms (LUTS) in the general populations of the USA, UK and Sweden using... |
| SourceID | proquest pubmed pascalfrancis crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 352 |
| SubjectTerms | Adult Aged Biological and medical sciences bother community‐survey Epidemiologic Methods epidemiology Female Humans Internet LUTS Male Medical sciences Middle Aged Nephrology. Urinary tract diseases prevalence Prostatism - epidemiology Quality of Life Sweden - epidemiology United Kingdom - epidemiology United States - epidemiology Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland Urination Disorders - epidemiology urology |
| Title | The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2009.08427.x https://www.ncbi.nlm.nih.gov/pubmed/19281467 https://www.proquest.com/docview/67496466 |
| Volume | 104 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYQhwqpKqUv0gL1oQcqNatN7NgJN6hAiEcPXSLtLbKdWEIs2dUmq5b-hP5qZuzsoiAOqOolsmKPHTsz9md7HoR8ibWKeKRZyBPNQ25ZFOooVqFiCVMiS3nG0Xb48oc4zfnZOBl3-k9oC-P9Q6wO3FAy3HyNAq5081jIofpoOO7cTqY8lgPEk6i6hfjo58qTFBR1USU9CcD2vlLPkxX1VqqXM9XAoFkf7eIpONpHt255OtkkN8uOea2Um8Gi1QPz55HPx__T89fkVYdi6aFnuy2yVtVvyIvL7p7-LfkL3Ednc3QljjMHnVo6wXBsFM_2oWHaonEWbe5uZ-30tqH7F_nV6Cu9ringUZqPDr_5xDlVdUlHvyqYHQ_ovGoWk7ahaBLj8o8fwtveYRtYC92Ht7465zr3HclPjq--n4Zd1IfQcMFkqLisUsV0OVRCSBvzlOkKNm1MlSaBLJMoAQ9bxpkxAObKIbcplJORLRUAWPaerNfTutom1JrU6Mwqk8Yld2hHlsCy2nAdM0BmAZHLP1yYziU6RuaYFL2tES9wqDFgZ1a4oS5-ByRaUc68W5Bn0Oz1mGhFiDHCZBanAfm85KoChBxvblRdTRdNISTPBLBwQD54ZntoFOhwsQuIcCzz7K8pjs5yTH38V8JPZMPfrKEy5A5Zb-eLahcAWqv3nOjdA_FYKnU |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9swFBajhW0wums379LqYQ8dzCG2ZNnuWzdasjbpwxJD3owkWzCWOiF2WNufsF_dcyQnxaUPZezFCEtHsuRzpE-38xHyOVQy4IFiPo8U97lhga-CUPqSRUyKNOEpx7vDo3MxyPjpNJq2dEB4F8b5h9gsuKFl2P4aDRwXpO9aOeQf9Ket38mEh3EPAOU2Enzb-dXPjS8pSGt5JZ0MAPfusZ57c-qMVc8WsoZmM47v4j5A2sW3doA6eU5m66q5cym_e6tG9fT1Ha-P_6nuL8hOC2TpkdO8l-RRWb0ij0ftVv1r8hcUkC6W6E0cOw86N3SGjGwUl_ehZNrg_SxaX10smvlFTQ-G2WT8hf6qKEBSmo2PvrrAGZVVQcd_SuggD-myrFezpqZ4K8bGH98y3F5hGZgLPYC3LjvrPfcNyU6OJ98Hfkv84GsuWOxLHpeJZKroSyFiE_KEqRLmbUwWOoIoHUkBD1OEqdaA54o-NwmkiwNTSMCwbJdsVfOqfEeo0YlWqZE6CQtuAU9cgNYqzVXIAJx5JF7_4ly3XtGRnGOWd2ZHPMemRs7ONLdNnV96JNhILpxnkAfI7HW0aCOINGFxGiYe2V-rVQ52jps3sirnqzoXMU8F6LBH3jptuy0U5HC884iwOvPgr8m_nWYYev-vgvvkyWAyGubDH-dnH8hTt9GGZyM_kq1muSo_AV5r1J61wxuZeS6Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhVAofTd12yQ69JBCvawtWZZ7S5MsaV6Ubgx7M5JsQcnGa9Ze2vQn5FdnxvJucMghlF6MsDSSJX8jfXrNEPIp1CrggWY-jzT3uWWBr4NQ-YpFTIlE8oTj3eHTM3GY8qNJNOnOP-FdGGcfYrXghprR9teo4FVu7yo5ZB8MJ53ZScnDeAB88jEXQ4kI3_-5MiUFaVu3kk4GeHv_VM-9OfWGqqeVqqHVrHN3cR8f7dPbdnwaPScXy5q5YykXg0WjB-bvHaOP_6fqL8izjsbSXYe7l-RRUb4i66fdRv1rcg3wo9UcbYlj10Fnlk7RHxvFxX0omDZ4O4vWV5dVM7us6c5Jej7-TH-VFAgpTce7X1zgmKoyp-PfBXSPX-m8qBfTpqZ4J6aNP7j1b3uFZWAudAfeuuxa27lvSDo6ON879Du3D77hgsW-4nEhFdP5UAkR25BLpguYtTGVmwiiTKQEPGweJsYAm8uH3EpIFwc2V8Bg2VuyVs7K4h2h1kijE6uMDHPe0p04B8xqw3XIgJp5JF7-4cx0NtHRNcc0682NeIZNjR47k6xt6uyPR4KVZOXsgjxAZqsHopUgOgmLk1B6ZHuJqgy0HLduVFnMFnUmYp4IgLBHNhzYbgsFORztPCJayDz4a7JvRymG3v-r4DZZ_7E_yk6-nx1_IE_cLhsejPxI1pr5otgEstborVYLbwDz0y1I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+prevalence+of+lower+urinary+tract+symptoms+%28LUTS%29+in+the+USA%2C+the+UK+and+Sweden%3A+results+from+the+Epidemiology+of+LUTS+%28EpiLUTS%29+study&rft.jtitle=BJU+international&rft.au=Coyne%2C+Karin+S.&rft.au=Sexton%2C+Chris+C.&rft.au=Thompson%2C+Christine+L.&rft.au=Milsom%2C+Ian&rft.date=2009-08-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=104&rft.issue=3&rft.spage=352&rft.epage=360&rft_id=info:doi/10.1111%2Fj.1464-410X.2009.08427.x&rft.externalDBID=10.1111%252Fj.1464-410X.2009.08427.x&rft.externalDocID=BJU8427 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |